NovaBridge Biosciences
Ownership
Ownership Structure
Who owns NovaBridge Biosciences (NBP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 55.6% of the shares are freely tradable; institutional investors hold 39.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Hillhouse Capital Advisors, Ltd. | 5.16 | 5,980,568 | +0.0 | 06/30/2026 |
| Morgan Stanley - Brokerage Accounts | 3.15 | 3,653,228 | -4.8 | 06/30/2026 |
| AIHC Capital Management Limited | 2.48 | 2,878,033 | +27.2 | 06/30/2026 |
| Siren, L.L.C. | 1.73 | 2,004,739 | -33.2 | 06/30/2026 |
| Marshall Wace Asset Management Ltd | 1.06 | 1,231,946 | +0.0 | 06/30/2026 |
| Candriam Luxembourg S.C.A. | 0.98 | 1,132,563 | +0.0 | 06/30/2026 |
| Adage Capital Partners Gp LLC | 0.86 | 1,000,000 | +0.0 | 06/30/2026 |
| Two Sigma Investments LLC | 0.73 | 851,348 | +0.0 | 06/30/2026 |
| Renaissance Technologies Corp | 0.65 | 758,226 | +178.3 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Belfius Equities Cure C Cap | 0.98 | 1,132,563 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Xu Cong Claire | EVP, Clinical Development | 304,201 | 252,487 $ | Aug 31, 2026 | direct |
| Cao Sean Wuxiong | Chief Bus. Development Officer | 266,467 | 221,168 $ | Sep 9, 2026 | direct |
| Dennis Phillip Andrew | Chief Medical Officer | 173,427 | 143,944 $ | Sep 18, 2026 | direct |
| Lenz Robert A. | Director | 17,218 | 14,291 $ | Aug 22, 2026 | direct |
| Woo Ian Ying | Director | 13,271 | 11,015 $ | Oct 15, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Woo Ian Ying | Director | Other | 13,271 | – | – |
| Sep 18, 2026 | Dennis Phillip Andrew | Chief Medical Officer | Sell | 8,209 | 0.71 | 5,828 |
| Sep 17, 2026 | Dennis Phillip Andrew | Chief Medical Officer | Other | 23,695 | – | – |
| Sep 9, 2026 | Cao Sean Wuxiong | Chief Bus. Development Officer | Sell | 107,978 | 0.74 | 79,904 |
| Sep 3, 2026 | Cao Sean Wuxiong | Chief Bus. Development Officer | Other | 104,236 | – | – |
| Sep 3, 2026 | Cao Sean Wuxiong | Chief Bus. Development Officer | Other | 235,136 | – | – |
| Aug 31, 2026 | Xu Cong Claire | EVP, Clinical Development | Sell | 3,282 | 0.79 | 2,593 |
| Aug 30, 2026 | Xu Cong Claire | EVP, Clinical Development | Other | 9,382 | – | – |
| Aug 22, 2026 | Lenz Robert A. | Director | Other | 17,218 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.